Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Melanie Rohr (NPI 1710276415)

Field	Value
Entity Type	Individual
Organization	Melanie Rohr
Address	1921 N Webb Rd
City	Wichita
State	KS
ZIP	67206
Taxonomy	Rheumatology Physician
NPI Enumerated	April 4, 2011

Payer Source	Total Paid
Medicare	$1.2M
Medicaid	$0

Key Findings

MELANIE ROHR is a Rheumatology Physician in WICHITA, KS with an NPI enumerated 2011-04-04 (~15 years ago). Her billing footprint is concentrated in Medicare with total Medicare revenue of $1.2M and no Medicaid billing on file, making her effectively a single-payer (Medicare) practice for the data observed.

Revenue is highly concentrated in three biologic drug codes: the precomputed top 3 codes account for 73.0% of Medicare revenue, led by J3262 ($350K, 27.4%), J0129 ($340.9K, 26.7%), and J1602 ($241.5K, 18.9%). These three drug codes together drive the majority of the practice’s Medicare income, indicating drug administration is the core revenue stream.

The code mix and descriptions point to an in-office biologics/infusion service line: J3262 (tocilizumab), J0129 (abatacept), and J1602 (golimumab) are high-cost rheumatology biologics, and administration/infusion activity is supported by 96365 (369 claims, $47 avg paid/claim, $17.3K revenue). This pattern suggests the practice operates an infusion/administration workflow rather than relying solely on office visit billings.

Bone-health therapies and DXA testing are a secondary service line: J0897 (denosumab) accounts for $110.2K (8.6%) and J3111 (romosozumab) accounts for $104.2K (8.2%) of Medicare revenue, with 77080 (DXA) also appearing ($1.7K). J0897 ranks #2243 of 10057 (77th percentile; typical, unremarkable volume) while J3111 ranks #573 of 970 (40th percentile; typical, unremarkable volume), consistent with meaningful but not dominant osteoporosis treatment activity.

Traditional evaluation-and-management visits represent a relatively small share of revenue compared with biologic drug administration: 99214 generated $40.8K (3.2%) from 469 claims and 99213 generated $22.2K (1.7%) from 364 claims. Both E/M codes rank highly by volume nationally (99214 at the 89th percentile and 99213 at the 90th percentile; both described as typical, unremarkable volume), indicating steady clinic visit activity even though these visits are not the primary revenue drivers.

Competitive standing across the top biologics is that of a modest national participant rather than a market leader: J3262 ranks #130 of 618 providers (79th percentile; typical, unremarkable volume), J1602 ranks #262 of 1041 (75th percentile; typical, unremarkable volume), and J0129 ranks #477 of 1221 (61th percentile; typical, unremarkable volume). Those percentiles show above-average presence on some biologics but do not indicate dominant national market share.

Operationally, the claim-level economics vary by drug: J3262 shows an unusually large claim count (70K claims) with a low average paid/claim ($5) yielding $350K revenue, while J0129 and J1602 have far higher avg paid/claim ($34 and $11 respectively) with far fewer claims. This combination of very high-frequency, low-unit payments for some biologic codes and lower-frequency, higher-unit payments for others is important for cashflow and inventory/administration planning.

The absence of any Medicaid billing on file ("none below") means the provider’s documented revenue exposure in this dataset is concentrated entirely in Medicare; for payer-mix and network strategy assessments this should be treated as effectively Medicare-only activity unless other data sources indicate Medicaid participation. This single-payer profile simplifies payer analysis but may limit conclusions about state Medicaid competitiveness or access for non-Medicare populations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	70,000	$10	$350K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	10,030	$30	$340.9K
J1602	Injection, golimumab, 1 mg, for intravenous use	21,950	$10	$241.4K
J0897	Injection, denosumab, 1 mg	6,120	$20	$110.2K
J3111	Injection, romosozumab-aqqg, 1 mg	13,020	$10	$104.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	470	$90	$40.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	360	$60	$22.2K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	370	$50	$17.3K
86481	The lab analyst performs a test to evaluate an antigen response to certain tuberculosis (TB) antibodies by enumerating T cells that produce gamma interferon.	90	$100	$8.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	80	$100	$7.2K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Melanie Rohr — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	8	20	8,000	$30	$291.5K
J3262	3	10	60,820	$1	$243K
J3111	6	10	17,700	$10	$198.5K
J1602	3	20	14,360	$10	$167.7K
J0897	31	180	2,160	$20	$81.5K
86235	14	20	280	$20	$30.8K
82306	27	160	40	$30	$27.1K
96413	40	80	80	$90	$26.3K
80053	61	350	150	$10	$18.6K
99214	576	4,310	120	$70	$16.4K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Melanie Rohr, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Timothy Shaver	KS	Rheumatology Physician	$3M	$0
Shadi Shahouri	KS	Rheumatology Physician	$1.9M	$0
Maya Estephan	KS	Internal Medicine Physician	$849.5K	$0
Rawaa Ebrahem	KS	Rheumatology Physician	$757.4K	$0
Stacy Wagner	KS	Medical Physician Assistant	$57.8K	$0
Kathleen Dang-pham	KS	Physician Assistant	$43.4K	$0
Jamie Agan	KS	Physician Assistant	$34.8K	$0
Praveena Gorantla	KS	Rheumatology Physician	$31.8K	$0

Nearby Providers

Other providers in the same ZIP code as Melanie Rohr, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Childrens Dentistry Of Wichita	KS	Pediatric Dentistry	$0	$32.8M
Trust Homecare, LLC	KS	Home Health Agency	$0	$28.4M
Good Shepherd Hospice Wichita LLC	KS	Community Based Hospice Care Agency	$0	$17.7M
Grene Vision Group LLC	KS	Ophthalmology Physician	$0	$6.3M
Anthem Wichita Management, LLC	KS	Alzheimer Center (Dementia Center)	$0	$4.3M
Justin Gooden	KS	Undersea and Hyperbaric Medicine (Preventive Medicine) Physician	$4.3M	$0
Jonas Lichty	KS	Oral and Maxillofacial Surgery (Dentist)	$2.6K	$2.9M
Homestead Of Crestview Operations LLC	KS	Assisted Living Facility	$0	$2.8M
Kansas Kids Heart Center, PA	KS	Pediatric Cardiology Physician	$0	$2.7M
Remy Blanchaert	KS	Oral and Maxillofacial Surgery (Dentist)	$4.1K	$2.4M

Melanie Rohr — Billing Profile & Reimbursement Data

Sign up for Melanie Rohr — Billing Profile & Reimbursement Data policy alerts

Melanie Rohr — Billing Profile & Reimbursement Data

Sign up for Melanie Rohr — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References